Synthesis and biological evaluation of NH2-acyl oseltamivir analogues as potent neuraminidase inhibitors.
Identifieur interne : 000A68 ( PubMed/Curation ); précédent : 000A67; suivant : 000A69Synthesis and biological evaluation of NH2-acyl oseltamivir analogues as potent neuraminidase inhibitors.
Auteurs : Kuanglei Wang [République populaire de Chine] ; Fei Yang [République populaire de Chine] ; Lihui Wang [République populaire de Chine] ; Kemin Liu [République populaire de Chine] ; Lu Sun [République populaire de Chine] ; Bin Lin [République populaire de Chine] ; Yaping Hu [République populaire de Chine] ; Boyu Wang [République populaire de Chine] ; Maosheng Cheng [République populaire de Chine] ; Yongshou Tian [République populaire de Chine]Source :
- European journal of medicinal chemistry [ 1768-3254 ] ; 2017.
Descripteurs français
- KwdFr :
- Antienzymes (), Antienzymes (pharmacologie), Antienzymes (synthèse chimique), Antiviraux (), Antiviraux (pharmacologie), Antiviraux (synthèse chimique), Oséltamivir (), Oséltamivir (pharmacologie), Oséltamivir (synthèse chimique), Relation dose-effet des médicaments, Relation structure-activité, Sialidase (antagonistes et inhibiteurs), Sialidase (métabolisme), Sous-type H1N1 du virus de la grippe A (), Sous-type H1N1 du virus de la grippe A (enzymologie), Sous-type H5N1 du virus de la grippe A (), Sous-type H5N1 du virus de la grippe A (enzymologie), Sous-type H7N9 du virus de la grippe A (), Sous-type H7N9 du virus de la grippe A (enzymologie), Structure moléculaire, Tests de sensibilité microbienne.
- MESH :
- antagonistes et inhibiteurs : Sialidase.
- enzymologie : Sous-type H1N1 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A, Sous-type H7N9 du virus de la grippe A.
- métabolisme : Sialidase.
- pharmacologie : Antienzymes, Antiviraux, Oséltamivir.
- synthèse chimique : Antienzymes, Antiviraux, Oséltamivir.
- Antienzymes, Antiviraux, Oséltamivir, Relation dose-effet des médicaments, Relation structure-activité, Sous-type H1N1 du virus de la grippe A, Sous-type H5N1 du virus de la grippe A, Sous-type H7N9 du virus de la grippe A, Structure moléculaire, Tests de sensibilité microbienne.
English descriptors
- KwdEn :
- Antiviral Agents (chemical synthesis), Antiviral Agents (chemistry), Antiviral Agents (pharmacology), Dose-Response Relationship, Drug, Enzyme Inhibitors (chemical synthesis), Enzyme Inhibitors (chemistry), Enzyme Inhibitors (pharmacology), Influenza A Virus, H1N1 Subtype (drug effects), Influenza A Virus, H1N1 Subtype (enzymology), Influenza A Virus, H5N1 Subtype (drug effects), Influenza A Virus, H5N1 Subtype (enzymology), Influenza A Virus, H7N9 Subtype (drug effects), Influenza A Virus, H7N9 Subtype (enzymology), Microbial Sensitivity Tests, Molecular Structure, Neuraminidase (antagonists & inhibitors), Neuraminidase (metabolism), Oseltamivir (chemical synthesis), Oseltamivir (chemistry), Oseltamivir (pharmacology), Structure-Activity Relationship.
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , chemical synthesis : Antiviral Agents, Enzyme Inhibitors, Oseltamivir.
- chemical , chemistry : Antiviral Agents, Enzyme Inhibitors, Oseltamivir.
- chemical , metabolism : Neuraminidase.
- chemical , pharmacology : Antiviral Agents, Enzyme Inhibitors, Oseltamivir.
- drug effects : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H5N1 Subtype, Influenza A Virus, H7N9 Subtype.
- enzymology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H5N1 Subtype, Influenza A Virus, H7N9 Subtype.
- Dose-Response Relationship, Drug, Microbial Sensitivity Tests, Molecular Structure, Structure-Activity Relationship.
Abstract
Neuraminidase inhibitors can deter nascent viruses from infecting intact cells by preventing their release from host cells. Herein, a neuraminidase inhibitor 11b absent of basic moieties was discovered in the process of searching for inhibitors targeting 150 cavity. It exhibited potent inhibitions against wild-type neuraminidases from group 1 (H5N1 and H1N1) and group 2 (H7N9) subtypes with IC50 values similar to those of oseltamivir carboxylate. Moreover, 11b showed moderate inhibitions against mutant neuraminidases from H5N1-H274Y and H1N1-H274Y with IC50 values of 2075 nM and 1382 nM, which were inferior to those of oseltamivir carboxylate (6095 nM and 4071 nM). The results were not consistent with the recognized SARs that a basic moiety was an indispensable part of a potent inhibitor.
DOI: 10.1016/j.ejmech.2017.10.004
PubMed: 29107426
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A68
Links to Exploration step
pubmed:29107426Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Synthesis and biological evaluation of NH<sub>2</sub>-acyl oseltamivir analogues as potent neuraminidase inhibitors.</title><author><name sortKey="Wang, Kuanglei" sort="Wang, Kuanglei" uniqKey="Wang K" first="Kuanglei" last="Wang">Kuanglei Wang</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Yang, Fei" sort="Yang, Fei" uniqKey="Yang F" first="Fei" last="Yang">Fei Yang</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Lihui" sort="Wang, Lihui" uniqKey="Wang L" first="Lihui" last="Wang">Lihui Wang</name><affiliation wicri:level="1"><nlm:affiliation>School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Kemin" sort="Liu, Kemin" uniqKey="Liu K" first="Kemin" last="Liu">Kemin Liu</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Sun, Lu" sort="Sun, Lu" uniqKey="Sun L" first="Lu" last="Sun">Lu Sun</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Lin, Bin" sort="Lin, Bin" uniqKey="Lin B" first="Bin" last="Lin">Bin Lin</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Hu, Yaping" sort="Hu, Yaping" uniqKey="Hu Y" first="Yaping" last="Hu">Yaping Hu</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Boyu" sort="Wang, Boyu" uniqKey="Wang B" first="Boyu" last="Wang">Boyu Wang</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Cheng, Maosheng" sort="Cheng, Maosheng" uniqKey="Cheng M" first="Maosheng" last="Cheng">Maosheng Cheng</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China. Electronic address: mscheng@263.net.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Tian, Yongshou" sort="Tian, Yongshou" uniqKey="Tian Y" first="Yongshou" last="Tian">Yongshou Tian</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China. Electronic address: yongshoutian988@163.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:29107426</idno><idno type="pmid">29107426</idno><idno type="doi">10.1016/j.ejmech.2017.10.004</idno><idno type="wicri:Area/PubMed/Corpus">000A68</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A68</idno><idno type="wicri:Area/PubMed/Curation">000A68</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A68</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Synthesis and biological evaluation of NH<sub>2</sub>-acyl oseltamivir analogues as potent neuraminidase inhibitors.</title><author><name sortKey="Wang, Kuanglei" sort="Wang, Kuanglei" uniqKey="Wang K" first="Kuanglei" last="Wang">Kuanglei Wang</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Yang, Fei" sort="Yang, Fei" uniqKey="Yang F" first="Fei" last="Yang">Fei Yang</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Lihui" sort="Wang, Lihui" uniqKey="Wang L" first="Lihui" last="Wang">Lihui Wang</name><affiliation wicri:level="1"><nlm:affiliation>School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Kemin" sort="Liu, Kemin" uniqKey="Liu K" first="Kemin" last="Liu">Kemin Liu</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Sun, Lu" sort="Sun, Lu" uniqKey="Sun L" first="Lu" last="Sun">Lu Sun</name><affiliation wicri:level="1"><nlm:affiliation>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Lin, Bin" sort="Lin, Bin" uniqKey="Lin B" first="Bin" last="Lin">Bin Lin</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Hu, Yaping" sort="Hu, Yaping" uniqKey="Hu Y" first="Yaping" last="Hu">Yaping Hu</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Boyu" sort="Wang, Boyu" uniqKey="Wang B" first="Boyu" last="Wang">Boyu Wang</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Cheng, Maosheng" sort="Cheng, Maosheng" uniqKey="Cheng M" first="Maosheng" last="Cheng">Maosheng Cheng</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China. Electronic address: mscheng@263.net.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author><author><name sortKey="Tian, Yongshou" sort="Tian, Yongshou" uniqKey="Tian Y" first="Yongshou" last="Tian">Yongshou Tian</name><affiliation wicri:level="1"><nlm:affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China. Electronic address: yongshoutian988@163.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016</wicri:regionArea></affiliation></author></analytic><series><title level="j">European journal of medicinal chemistry</title><idno type="eISSN">1768-3254</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemical synthesis)</term><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (pharmacology)</term><term>Dose-Response Relationship, Drug</term><term>Enzyme Inhibitors (chemical synthesis)</term><term>Enzyme Inhibitors (chemistry)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza A Virus, H1N1 Subtype (enzymology)</term><term>Influenza A Virus, H5N1 Subtype (drug effects)</term><term>Influenza A Virus, H5N1 Subtype (enzymology)</term><term>Influenza A Virus, H7N9 Subtype (drug effects)</term><term>Influenza A Virus, H7N9 Subtype (enzymology)</term><term>Microbial Sensitivity Tests</term><term>Molecular Structure</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Neuraminidase (metabolism)</term><term>Oseltamivir (chemical synthesis)</term><term>Oseltamivir (chemistry)</term><term>Oseltamivir (pharmacology)</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antienzymes ()</term><term>Antienzymes (pharmacologie)</term><term>Antienzymes (synthèse chimique)</term><term>Antiviraux ()</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (synthèse chimique)</term><term>Oséltamivir ()</term><term>Oséltamivir (pharmacologie)</term><term>Oséltamivir (synthèse chimique)</term><term>Relation dose-effet des médicaments</term><term>Relation structure-activité</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sialidase (métabolisme)</term><term>Sous-type H1N1 du virus de la grippe A ()</term><term>Sous-type H1N1 du virus de la grippe A (enzymologie)</term><term>Sous-type H5N1 du virus de la grippe A ()</term><term>Sous-type H5N1 du virus de la grippe A (enzymologie)</term><term>Sous-type H7N9 du virus de la grippe A ()</term><term>Sous-type H7N9 du virus de la grippe A (enzymologie)</term><term>Structure moléculaire</term><term>Tests de sensibilité microbienne</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H5N1 Subtype</term><term>Influenza A Virus, H7N9 Subtype</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Sous-type H7N9 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza A Virus, H5N1 Subtype</term><term>Influenza A Virus, H7N9 Subtype</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Microbial Sensitivity Tests</term><term>Molecular Structure</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Relation dose-effet des médicaments</term><term>Relation structure-activité</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Sous-type H7N9 du virus de la grippe A</term><term>Structure moléculaire</term><term>Tests de sensibilité microbienne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neuraminidase inhibitors can deter nascent viruses from infecting intact cells by preventing their release from host cells. Herein, a neuraminidase inhibitor 11b absent of basic moieties was discovered in the process of searching for inhibitors targeting 150 cavity. It exhibited potent inhibitions against wild-type neuraminidases from group 1 (H5N1 and H1N1) and group 2 (H7N9) subtypes with IC<sub>50</sub> values similar to those of oseltamivir carboxylate. Moreover, 11b showed moderate inhibitions against mutant neuraminidases from H5N1-H274Y and H1N1-H274Y with IC<sub>50</sub> values of 2075 nM and 1382 nM, which were inferior to those of oseltamivir carboxylate (6095 nM and 4071 nM). The results were not consistent with the recognized SARs that a basic moiety was an indispensable part of a potent inhibitor.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29107426</PMID><DateCompleted><Year>2017</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1768-3254</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><PubDate><Year>2017</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>European journal of medicinal chemistry</Title><ISOAbbreviation>Eur J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Synthesis and biological evaluation of NH<sub>2</sub>-acyl oseltamivir analogues as potent neuraminidase inhibitors.</ArticleTitle><Pagination><MedlinePgn>648-656</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0223-5234(17)30796-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2017.10.004</ELocationID><Abstract><AbstractText>Neuraminidase inhibitors can deter nascent viruses from infecting intact cells by preventing their release from host cells. Herein, a neuraminidase inhibitor 11b absent of basic moieties was discovered in the process of searching for inhibitors targeting 150 cavity. It exhibited potent inhibitions against wild-type neuraminidases from group 1 (H5N1 and H1N1) and group 2 (H7N9) subtypes with IC<sub>50</sub> values similar to those of oseltamivir carboxylate. Moreover, 11b showed moderate inhibitions against mutant neuraminidases from H5N1-H274Y and H1N1-H274Y with IC<sub>50</sub> values of 2075 nM and 1382 nM, which were inferior to those of oseltamivir carboxylate (6095 nM and 4071 nM). The results were not consistent with the recognized SARs that a basic moiety was an indispensable part of a potent inhibitor.</AbstractText><CopyrightInformation>Copyright © 2017. Published by Elsevier Masson SAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kuanglei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lihui</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Life Sciences and Biopharmaceutical Sciences, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Kemin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yaping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Boyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Maosheng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China. Electronic address: mscheng@263.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Yongshou</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang 110016, PR China. Electronic address: yongshoutian988@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Med Chem</MedlineTA><NlmUniqueID>0420510</NlmUniqueID><ISSNLinking>0223-5234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>20O93L6F9H</RegistryNumber><NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber><NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064766" MajorTopicYN="N">Influenza A Virus, H7N9 Subtype</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">150 cavity</Keyword><Keyword MajorTopicYN="N">Influenza virus</Keyword><Keyword MajorTopicYN="N">Neuraminidase inhibitors</Keyword><Keyword MajorTopicYN="N">Oseltamivir analogues</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>05</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29107426</ArticleId><ArticleId IdType="pii">S0223-5234(17)30796-1</ArticleId><ArticleId IdType="doi">10.1016/j.ejmech.2017.10.004</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000A68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:29107426
|texte= Synthesis and biological evaluation of NH2-acyl oseltamivir analogues as potent neuraminidase inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:29107426" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |